Tags

Type your tag names separated by a space and hit enter

Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
J Virol Methods. 2016 Feb; 228:84-90.JV

Abstract

The highly conserved extracellular domain of M2 protein (M2e) of influenza A viruses has limited immunogenicity on its own. Hence, aiming to enhance immunogenicity of M2e protein, optimal approaches remain to be established. In this study, we created recombinant fusion protein vaccines by linking M2e consensus sequence of influenza A viruses with C-terminal domain of human serum albumin (HSA). Then HSA/M2e recombinant fusion protein was studied. Our results showed that HSA/M2e could induce strong anti-M2e specific humoral immune responses in the established mice model. Administration of HSA/M2e with Freund's adjuvant resulted in a higher number of IFN-γ-producing cells compared to HSA/M2e or M2e peptide emulsified in Freund's adjuvant. Furthermore, HSA/M2e was able to reduce viral load in the mice lungs and provide significant protection against lethal challenge with an H1N1 or an H3N2 virus compared to controls. In conclusion, this study has demonstrated a potential vaccine that could provide protection in preventing the threat of influenza outbreak because of rapid variation of the influenza virus.

Authors+Show Affiliations

Department of Central Laboratory, China-Japan Union Hospital, Jilin University, Changchun, China.Department of Urology, The First Hospital, Jilin University, Changchun, China.Department of Infectious Disease, The Second Affiliated Hospital, China Medical University, Shenyang, China.Department of Biological Engineering, College of Pharmacy, Jilin University, Changchun, China.Department of Biological Engineering, College of Pharmacy, Jilin University, Changchun, China.Department of Biological Engineering, College of Pharmacy, Jilin University, Changchun, China.Department of Biological Engineering, College of Pharmacy, Jilin University, Changchun, China. Electronic address: weian_hui@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26615805

Citation

Mu, Xupeng, et al. "Protection Against Influenza a Virus By Vaccination With a Recombinant Fusion Protein Linking Influenza M2e to Human Serum Albumin (HSA)." Journal of Virological Methods, vol. 228, 2016, pp. 84-90.
Mu X, Hu K, Shen M, et al. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). J Virol Methods. 2016;228:84-90.
Mu, X., Hu, K., Shen, M., Kong, N., Fu, C., Yan, W., & Wei, A. (2016). Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). Journal of Virological Methods, 228, 84-90. https://doi.org/10.1016/j.jviromet.2015.11.014
Mu X, et al. Protection Against Influenza a Virus By Vaccination With a Recombinant Fusion Protein Linking Influenza M2e to Human Serum Albumin (HSA). J Virol Methods. 2016;228:84-90. PubMed PMID: 26615805.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA). AU - Mu,Xupeng, AU - Hu,Kebang, AU - Shen,Mohan, AU - Kong,Ning, AU - Fu,Changhao, AU - Yan,Weiqun, AU - Wei,Anhui, Y1 - 2015/11/23/ PY - 2014/11/25/received PY - 2015/11/18/revised PY - 2015/11/19/accepted PY - 2015/12/1/entrez PY - 2015/12/1/pubmed PY - 2016/10/25/medline KW - HSA KW - Immune protection KW - Influenza A virus KW - M2e KW - Vaccine SP - 84 EP - 90 JF - Journal of virological methods JO - J Virol Methods VL - 228 N2 - The highly conserved extracellular domain of M2 protein (M2e) of influenza A viruses has limited immunogenicity on its own. Hence, aiming to enhance immunogenicity of M2e protein, optimal approaches remain to be established. In this study, we created recombinant fusion protein vaccines by linking M2e consensus sequence of influenza A viruses with C-terminal domain of human serum albumin (HSA). Then HSA/M2e recombinant fusion protein was studied. Our results showed that HSA/M2e could induce strong anti-M2e specific humoral immune responses in the established mice model. Administration of HSA/M2e with Freund's adjuvant resulted in a higher number of IFN-γ-producing cells compared to HSA/M2e or M2e peptide emulsified in Freund's adjuvant. Furthermore, HSA/M2e was able to reduce viral load in the mice lungs and provide significant protection against lethal challenge with an H1N1 or an H3N2 virus compared to controls. In conclusion, this study has demonstrated a potential vaccine that could provide protection in preventing the threat of influenza outbreak because of rapid variation of the influenza virus. SN - 1879-0984 UR - https://www.unboundmedicine.com/medline/citation/26615805/Protection_against_influenza_A_virus_by_vaccination_with_a_recombinant_fusion_protein_linking_influenza_M2e_to_human_serum_albumin__HSA__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-0934(15)00377-8 DB - PRIME DP - Unbound Medicine ER -